Literature DB >> 19049763

Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes.

Julie E Bauman1, Michael S Mulligan, Renato G Martins, Brenda F Kurland, Keith D Eaton, Douglas E Wood.   

Abstract

BACKGROUND: Isolated local relapse occurs in 24% to 35% of patients after definitive chemoradiation for locally advanced non-small cell lung cancer. Although originally considered inoperable, select patients are referred for surgical salvage. We describe a series of salvage lung resection after curative-intent radiation.
METHODS: Twenty-four consecutive patients from 1997 to 2005 were identified retrospectively. Medical records reviewed. Patients were grouped by surgical indication: A, obvious relapse by computed tomography (CT), 7 patients; B, abnormal fluorodeoxyglucose-positron emission tomography (FDG-PET), 12; C, delayed conversion to trimodality, 4; and D, chronic bronchopleural fistula, 1.
RESULTS: All patients received definitive radiation (median, 63.9 Gray), 22 with concurrent chemotherapy. Original staging included cardiothoracic surgical consultation in 4. Median time from radiation to resection was 21 weeks. Twenty-four patients underwent 25 resections: one wedge, 10 lobectomies, 4 bilobectomies, and 10 pneumonectomies. Nineteen flaps were performed, 16 omental. Fourteen had complications, including one death from adult respiratory distress syndrome. Viable tumor was found in 19 patients. Median overall survival was 30 months (12 months, group A; 43 months, group B). Estimated 3-year survival was 47%. The Kaplan-Meier survival curve for group B was superior to that for group A (p = 0.019).
CONCLUSIONS: Salvage lung resection after definitive chemoradiation is feasible, with encouraging survival. Surgical indication is predictive, with higher survival among patients undergoing resection for abnormal FDG-PET than for obvious relapse by CT. FDG-PET should be studied prospectively in selecting patients for salvage lung resection. Systematic staging may have increased primary incorporation of surgery, minimizing the need for late salvage.

Entities:  

Mesh:

Year:  2008        PMID: 19049763     DOI: 10.1016/j.athoracsur.2008.07.042

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  23 in total

1.  The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.

Authors:  Pamela Samson; Aalok Patel; Cliff G Robinson; Daniel Morgensztern; Su-Hsin Chang; Graham A Colditz; Saiama Waqar; Traves D Crabtree; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-08-25       Impact factor: 4.330

Review 2.  Salvage surgery after high-dose radiotherapy.

Authors:  Annemie Van Breussegem; Jeroen M Hendriks; Patrick Lauwers; Paul E Van Schil
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

3.  Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation.

Authors:  Patrick Kelly; Peter A Balter; Neal Rebueno; Hadley J Sharp; Zhongxing Liao; Ritsuko Komaki; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-08       Impact factor: 7.038

Review 4.  Current Topics on Salvage Thoracic Surgery in Patients with Primary Lung Cancer.

Authors:  Hidetaka Uramoto
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-03-04       Impact factor: 1.520

5.  Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment.

Authors:  Jeremy M Kilburn; Jeffrey G Kuremsky; A William Blackstock; Michael T Munley; William T Kearns; William H Hinson; James F Lovato; Antonius A Miller; William J Petty; James J Urbanic
Journal:  Radiother Oncol       Date:  2014-01-17       Impact factor: 6.280

Review 6.  Surgical management of advanced non-small cell lung cancer.

Authors:  Gonzalo Varela; Pascal Alexandre Thomas
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 7.  Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions.

Authors:  Carmen Vallejo Ocańa; Pilar Garrido López; Ignacio Muguruza Trueba
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

8.  Pulmonary resection after chemoradiotherapy for advanced non-small cell lung cancer: the impact of presurgical radiation therapy.

Authors:  Takeshi Shiraishi; Masafumi Hiratsuka; Jun Yanagisawa; Sou Miyahara; Yasuhiro Yoshida; Yoshifumi Makimoto; Daisuke Hamatake; Shin-ichi Yamashita; Akinori Iwasaki
Journal:  Surg Today       Date:  2013-02-19       Impact factor: 2.549

9.  National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer.

Authors:  Aalok P Patel; Traves D Crabtree; Jennifer M Bell; Tracey J Guthrie; Clifford G Robinson; Daniel Morgensztern; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; Jeffrey D Bradley; G Alexander Patterson; Bryan F Meyers; Varun Puri
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

10.  Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.

Authors:  Jeremy M Kilburn; Scott C Lester; John T Lucas; Michael H Soike; A William Blackstock; William T Kearns; William H Hinson; Antonius A Miller; William J Petty; Michael T Munley; James J Urbanic
Journal:  J Thorac Oncol       Date:  2014-04       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.